Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Amgen Inc (AMGN)

Amgen Inc (AMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 119,571,568
  • Shares Outstanding, K 589,807
  • Annual Sales, $ 23,362 M
  • Annual Income, $ 7,842 M
  • 60-Month Beta 1.11
  • Price/Sales 5.26
  • Price/Cash Flow 11.03
  • Price/Book 12.81

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate 3.70
  • Number of Estimates 10
  • High Estimate 4.08
  • Low Estimate 3.20
  • Prior Year 3.56
  • Growth Rate Est. (year over year) +3.93%

Price Performance

See More
Period Period Low Period High Performance
1-Month
177.05 +14.50%
on 03/23/20
216.39 -6.31%
on 03/05/20
+3.00 (+1.50%)
since 02/28/20
3-Month
177.05 +14.50%
on 03/23/20
243.85 -16.86%
on 01/16/20
-38.80 (-16.06%)
since 12/27/19
52-Week
166.30 +21.91%
on 05/15/19
244.99 -17.25%
on 12/17/19
+12.75 (+6.71%)
since 03/29/19

Most Recent Stories

More News
Amgen Establishes Wholly-Owned Affiliate In Japan

Amgen (NASDAQ:AMGN) today announced that it has consummated the purchase from Astellas of 49% of shares of Amgen Astellas BioPharma K.K. (AABP), a joint venture between Amgen and Astellas established in...

AMGN : 202.73 (-2.76%)
Watch for Amgen Inc to Potentially Pullback After Gaining 3.68% Yesterday

Amgen Inc (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $200.05 to a high of $207.00. Yesterday, the shares gained 3.7%, which took the trading range above the 3-day high of $205.87...

AMGN : 202.73 (-2.76%)
Amgen Inc Set to Possibly Pullback After Yesterday's Rally of 3.68%

Amgen Inc (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $200.05 to a high of $207.00. Yesterday, the shares gained 3.7%, which took the trading range above the 3-day high of $205.87...

AMGN : 202.73 (-2.76%)
Hormone Replacement Therapy Market to Reach USD 20.76 Billion by 2026; Increasing Cases of Hormone-Related Disorders to Augment Growth, states Fortune Business Insights(TM)

The global hormone replacement therapy market size is predicted to reach USD 20.76 billion by 2026, exhibiting a CAGR of 6.0% during the forecast period. The increasing cases of hormone-related disorders...

ABBV : 76.19 (+1.26%)
AGN : 177.10 (+0.45%)
AMGN : 202.73 (-2.76%)
LLY : 138.72 (+0.20%)
ENDP : 3.70 (+1.09%)
MKKGY : 20.4000 (+3.24%)
3 Top Dividend Stocks to Maximize Your Retirement Income - March 30, 2020

The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate...

AAT : 25.00 (+1.34%)
ADM : 35.18 (-1.81%)
AMGN : 202.73 (-2.76%)
LifeMax Launches AmMax Bio Following The License Of Worldwide Rights to a Clinical Stage Orphan Asset From Amgen

LifeMax Laboratories, Inc. ("LifeMax"), a private company focused on treating orphan diseases that have few or no therapeutic options, today announced the formation of AmMax Bio, Inc. ("AmMax") and an...

AMGN : 202.73 (-2.76%)
IPXL : 18.30 (unch)
Amgen Announces Positive Results At ACC.20/WCC From Phase 3B Study Of Repatha® (Evolocumab) In People Living With HIV Who Have High LDL-Cholesterol

Amgen (NASDAQ:AMGN) today announced positive results from the EvolocumaB Effect on LDL-C LowerIng in SubJEcts with Human Immunodeficiency ViRus and INcreased Cardiovascular RisK (BEIJERINCK) study evaluating...

AMGN : 202.73 (-2.76%)
Pharma, Biotech Players Step Up Efforts Against Coronavirus

Several pharma & biotech companies announce their plan to fight coronavirus pandemic and state anticipated unfavorable impact of the outbreak on their business.

PFE : 32.64 (-0.09%)
MRK : 76.94 (-0.01%)
MYL : 14.91 (-1.06%)
LLY : 138.72 (+0.20%)
BMY : 55.74 (+2.48%)
AMGN : 202.73 (-2.76%)
CytomX & Astellas Collaborate to Develop Novel Cancer Therapy

CytomX (CTMX) and Astellas Pharma sign collaboration agreement to develop novel cancer therapy using CytomX's Probody therapeutic technology platform.

BMY : 55.74 (+2.48%)
AMGN : 202.73 (-2.76%)
ABBV : 76.19 (+1.26%)
CTMX : 7.67 (+14.48%)
Amgen And The Amgen Foundation Commit Up To $12.5 Million To Support COVID-19 Relief Efforts

Amgen (NASDAQ:AMGN) and the Amgen Foundation today announced an initial commitment of up to $12.5 million to support U.S. and global relief efforts to address critical needs in communities impacted by...

AMGN : 202.73 (-2.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade AMGN with:

Business Summary

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice...

See More

Key Turning Points

2nd Resistance Point 210.10
1st Resistance Point 206.42
Last Price 202.73
1st Support Level 199.87
2nd Support Level 197.01

See More

52-Week High 244.99
Fibonacci 61.8% 214.93
Fibonacci 50% 205.65
Last Price 202.73
Fibonacci 38.2% 196.36
52-Week Low 166.30

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar